FOLH1 and prostate cancer: Improved diagnostic capabilities from mpMRI and, more recently, PSMA PET/CT (now subsidised by the MBS), has contributed to reducing unnecessary biopsies and providing greater accuracy in biopsy targeting potential clinically significant prostate cancer, thereby reducing harm.